Anna Dietz, Siham Lazam, Patrick Montant, Fabien Chenot, Jamila Boulif, Christophe de Meester, David Vancraeynest, Anne-Catherine Pouleur, Bernhard Gerber, Agnès Pasquet, Jean-Louis VanoverscheldePublished in the journal : June 2016Category : Mémoires de Recherche Clinique
Severe degenerative mitral regurgitation (MR) is a progressive disease that impairs long-term prognosis...
Jessica de Jesus Azevedo, MC. Chiti, MM. Dolmans, R. Orellana, M. Soares, F. Paulini, J. Donnez, CA. AmorimPublished in the journal : June 2016Category : Mémoires de Recherche Clinique
Thousands of women suffering from malignant diseases can now be treated by chemotherapy, radiotherapy or bone marrow transplantation...
Post-transplantation lymphoproliferative disease (PTLD) is a serious complication in liver-transplanted children, most often related to Epstein-Barr virus (EBV) infection...
Nicolas Bonnet, Françoise Smets, Françis Veyckemans, Thibault Helleputte, Stéphane Eeckhoudt, Cédric Hermans, Etienne Sokal, Xavier StephennePublished in the journal : June 2016Category : Mémoires de Recherche Clinique
Cirrhotic children who are waitlisted for liver transplantation are prone to bleeding from ruptured esophageal varices, with Grade 2-3 varices and red signs as known risk factors...
C. Colmant, D. Maiter, B.Vandeleene, M. Baeck, L. de MontjoyePublished in the journal : September 2015Category : Dermatology
We here report on the “PEAU’se dermatologique” meeting that took place on October 22, 2015, dedicated to dermatological and endocrine diseases. Professor D. Maiter gave us the clues to optimal corticosteroid use in dermatological practice, from treatment initiation to withdrawal. Next, Professor B. Vandeleene reminded us of the cornerstones of diabetic foot management. Finally, Professor M. Baeck presented several clinical cases of dermatological diseases in the diabetic patient.
CADASIL disease is a rare autosomal dominant hereditary angiopathy, primarily characterized by significant white matter damage on MRI. We have herein described a case of Cadasil disease discovered somewhat fortuitously, owing to its insidious symptom onset and the causal mutation 's strongly suspected transmission to the patient’s son.
On February 16th, a round table was held in Brussels dealing with new oral anticoagulants. On this occasion, Belgian experts exchanged views with Professor Giancarlo Agnelli.
Precocious puberty (PP) is a most common condition encountered in pediatric endocrinology practice. Articles reporting on increasingly early pubertal development have recently been published in the lay press, thus resulting in numerous questions from parents regarding their children's pubertal development. PP can be defined as the onset of secondary sexual characteristics, along with accelerated growth and bone maturation, occurring earlier than usual, e.g., prior to the age of 8 years in girls and 9 in boys. PP etiologies can be divided into gonadotropinreleasing hormone (GnRH)-dependent and GnRH-independent causes. GnRHdependent PP, often referred to as central PP, is usually treated using GnRHagonists.
Direct oral anticoagulants (DoaCs) offer significant benefits for the treatment of nonvalvular atrial fibrillation and venous thromboembolism. these agents are simpler to use than others, as they do not require routine laboratory monitoring and dose adjustment. moreover, DoaCs have been shown to reduce severe bleedings, and especially intracranial bleedings, as compared to vitamin k antagonists. real-life clinical data confirmed these benefits that had previously been shown in randomized clinical trials.
This article describes several advances made in the dyslipidemia and cardiovascular prevention fields. These novelties pertain to the three steps of prevention: prediction including screening for two common, but often ignored, genetic abnormalities, namely familial hypercholesterolemia and elevated lipoprotein(a) levels, planning with the emergence in recommendations of a new target called "non-HDL cholesterol or non-HDL-C" in addition to the conventional "LDL-cholesterol or LDL-C" target, and prescription with the possible option of combining statins with other therapeutic classes.